Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment
Stopped Former PI left institution and had plans to continue at another institution.
Conditions
- HER-2 Positive Gastric Cancer
- Gastrooesophageal Cancer
- Esophageal Cancer
Interventions
- DRUG: Afatinib
- DRUG: Paclitaxel
Sponsor
Columbia University
Collaborators